Clinical trial NCT06839209: Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
Official title: Pilot Study to Evaluate Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Clostridium; Difficile, As Cause of Disease Classified Elsewhere
Clostridium Difficile Diarrhea
Keywords: clostridium difficile
clostridium
cdad
Lead sponsor: ABResearch S.r.l.
Sponsor class: INDUSTRY
Collaborators: name: Nextrasearch S.r.l.s.
First posted: 2025-02-21
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Cohort A: 1 g of Toxclean once a day for 28 days plus SoC therapy Cohort B: 1 g of Toxclean twice daily for 28 days plus SoC therapy
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.

Eligible subjects will be adult patients with recurrent CDAD. Recurrent CDAD, for the purpose of this protocol, is defined as one or more new episode of diarrhea (Ned) within two months from the end of the SoC treatment. The objective of this pilot study is to evaluate whether 1 or 2 grams of Toxclean powder is orally administrable and well tolerated as add on treatment to SoC in patients with recurrent CDAD.

Detailed description: This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.

Eligible subjects will be adult patients with recurrent CDAD. Recurrent CDAD, for the purpose of this protocol, is defined as one or more new episode of diarrhea (Ned) within two months from the end of the SoC treatment. The objective of this pilot study is to evaluate whether 1 or 2 grams of Toxclean powder is orally administrable and well tolerated as add on treatment to SoC in patients with recurrent CDAD. Primary

* Percentage of patients that complete Toxclean schedule treatment; Secondary
* Safety and tolerability of two different dosage of oral Toxclean treatment;
* Reduction of toxin amount in fecal sample;
* Clinical response after 28-day oral administration of two different dosage of TOXCLEAN in combination with SoC therapy;
* CDAD symptoms improvements during treatment and follow up periods;
* Fecal concentration of Toxclean;

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years, male or female, at the time of informed consent
* Signed informed consent by patient, or where applicable, patient's legally authorized representative;
* Diagnosis of recurrent CDAD, defined as those episodes of C. Difficile associated diarrhea occurring 2-8 weeks after either the symptoms resolution of a previous CDAD episode or C. difficile negativization of fecal sample.
* Detection of C. difficile toxins by nucleic acid amplification tests (NAAT), EIA or GDH;
* Received at least one course of adequate antibiotic therapy for CDAD (≥ 10 days of vancomycin at a dose of ≥125 mg four times per day, ≥ 10 days of metronidazole at a dose of 500mg three times per day or fidaxomixin 200mg twice a day for 10 days)

Exclusion Criteria:

* History of C. difficile complicating inflammatory bowel disease (Crohn's disease, ulcerative colitis), or history of bowel resection surgery (other than uncomplicated appendectomy) or history of other infectious diarrhea or diarrhea of unknown etiology since the initial episode of CDAD;
* Participants who require oral anticoagulant medications, including but not limited to warfarin and NOACs (novel oral anticoagulants);
* Major gastrointestinal surgery within 3 months of enrollment;
* History of swallowing difficulties, including dysphagia or odynophagia for liquids or solids;
* Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
* Consumption of the following prescription medications during the current enrollment episode: Bezlotuxamab/Zinplava Is pregnant or lactating Known hypersensitivity to the active principle or excipients

Primary outcomes:
measure: Percentage of patients that complete Toxclean schedule treatment
timeFrame: 28 days
Secondary outcomes:
measure: the assessment of the safety and tolerability of two different dosage of oral Toxclean treatment
timeFrame: 28 days
measure: the clinical response after 14-day oral administration of two different dosage of TOXCLEAN in combination with SoC therapy;
timeFrame: 14 days
measure: the CDAD symptoms improvements during treatment and follow up periods
timeFrame: 2 months
measure: Measurement of Toxclean fecal concentration of Toxclean
timeFrame: 28 days
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Policlinico Gemelli
Study officials:
affiliation: Direttore U.O.C. GASTROENTEROLOGIA Policlinico Gemelli
name: Giovanni Cammarota, Professor
role: PRINCIPAL_INVESTIGATOR
References: